Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA ...
After mulling its options for the past few months, Protagonist Therapeutics has decided to pocket $475 million from Takeda ...
City’s largest biotech employer has cut more than 1,000 jobs in the last two years and is consolidating offices around the ...
Takeda Pharmaceutical (TSE:4502) has ended its collaborative research agreement with Veritas In Silico Inc. on mRNA targeted ...
Pharmaceutical company Takeda has hired Jennifer Smoter to be its chief communications and governance officer. In this role ...
Takeda has pulled back from a research collaboration with a fellow Japanese life sciences company, ending work to discover new small molecules that target mRNA. | Takeda has pulled back from a ...
Zacks Investment Research on MSN
ADMA vs Takeda: Which plasma therapy stock is the better buy today?
ADMA Biologics ADMA and Takeda TAK are prominent players in the plasma-derived immunoglobulin space. ADMA focuses on ...
Takeda Pharmaceutical said Tuesday it has committed up to a staggering $6 billion—including $4 billion upfront—to acquire from Nimbus Therapeutics a candidate for multiple autoimmune diseases that is ...
Takeda Pharmaceuticals, Japan's largest drugmaker, has undergone a sweeping transformation under CEO Christophe Weber, emerging as one of the world's leading pharmaceutical companies. The company's ...
Takeda Pharmaceutical struck one of the biggest life science deals of 2022, acquiring a clinical-stage Nimbus Therapeutics drug addressing a promising new target for autoimmune disorders. Other than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results